Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Chemical Therapeutics

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman and James C. Cusack
Roberto A. Salas Fragomeni
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hye Won Chung
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosef Landesman
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Senapedis
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Richard Saint-Martin
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hensin Tsao
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith T. Flaherty
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Shacham
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kauffman
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Cusack
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-12-1171 Published July 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: April 2013 to January 2021

AbstractFull-text HTMLPDF
Total435225431714

Cited By

Article Information

Volume 12, Issue 7, pp. 1171-1179

DOI 
https://doi.org/10.1158/1535-7163.MCT-12-1171
PubMed 
23615632

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received December 4, 2012
  • Revision received April 17, 2013
  • Accepted April 17, 2013
  • Published first April 24, 2013.

Article Versions

  • Previous version (April 24, 2013 - 14:18).
  • Previous version (June 27, 2013 - 14:10).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2013 American Association for Cancer Research.

Author Information

  1. Roberto A. Salas Fragomeni1,2,
  2. Hye Won Chung1,2,
  3. Yosef Landesman5,
  4. William Senapedis5,
  5. Jean-Richard Saint-Martin5,
  6. Hensin Tsao1,3,
  7. Keith T. Flaherty1,4,
  8. Sharon Shacham5,
  9. Michael Kauffman5, and
  10. James C. Cusack1,2
  1. Authors' Affiliations: 1Harvard Medical School; 2Division of Surgical Oncology, Departments of 3Dermatology and 4Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston; and 5Karyopharm Therapeutics, Natick, Massachusetts
  1. Corresponding Author:
    James C. Cusack, Division of Surgical Oncology, Massachusetts General Hospital, Yawkey 7th Floor, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4093; Fax: 617-724-3895; E-mail: jcusack{at}partners.org
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 12 (7)
July 2013
Volume 12, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman and James C. Cusack
Mol Cancer Ther July 1 2013 (12) (7) 1171-1179; DOI: 10.1158/1535-7163.MCT-12-1171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman and James C. Cusack
Mol Cancer Ther July 1 2013 (12) (7) 1171-1179; DOI: 10.1158/1535-7163.MCT-12-1171
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Microtubule Inhibitor Destabilizes HIF-1α mRNA
  • PG545 Reduces Pancreatic Tumor Progression
Show more Chemical Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement